ENO1 and breast cancer: Notably, we observed the same phosphorylation site of ENO1 at serine 419, previously reported as a tumor-specific marker in TN BC progression [54], highlighting the potential of plasma EV markers to reflect key candidate markers studied in cells or tissue (Fig. 5).